Čájehuvvojit 1 - 20 oktiibuot 28 bohtosis ohcui "Dacomitinib"', ohcanáigi: 0,18s Aiddostahte ozu
  1. 1
    Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs

    Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs Dahkki Hsu-Yuan Chen, Chia-Hung Chen, Wei-Chih Liao, Yu-Chao Lin, Hung-Jen Chen, Te-Chun Hsia, Wen-Chien Cheng, Chih-Yen Tu

    Almmustuhtton 2024-10-01
    Fáttát:
    Viečča ollesdeavstta
    Artihkal
  2. 2
    Virtual screening of Osimertinib and Dacomitinib Analogues with potential activity on EGFR (T790M and l858R Mutations) for non-small cell lung cancer treatment

    Virtual screening of Osimertinib and Dacomitinib Analogues with potential activity on EGFR (T790M and l858R Mutations) for non-small cell lung cancer treatment Dahkki Leydis Luna Torres, Neyder Contreras Puentes, Antistio Avíz Amador

    Almmustuhtton 2021-10-01
    Fáttát:
    Viečča ollesdeavstta
    Artihkal
  3. 3
    Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment

    Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment Dahkki Hong-Shuai Li, Guang-Jian Yang, Yan Wang

    Almmustuhtton 2021-04-01
    Fáttát:
    Viečča ollesdeavstta
    Artihkal
  4. 4
    Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases

    Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases Dahkki Jinyao Zhang, Yan Wang, Ziling Liu, Lin Wang, Yu Yao, Yutao Liu, Xue Zhi Hao, Jianyang Wang, Puyuan Xing, Junling Li

    Almmustuhtton 2021-12-01
    Fáttát:
    Viečča ollesdeavstta
    Artihkal
  5. 5
    Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study)

    Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and... Dahkki Bo Zhang, Chunlei Shi, Zhiqiang Gao, Hua Zhong, Liwen Xiong, Aiqin Gu, Weimin Wang, Tianqing Chu, Wei Zhang, Huimin Wang, Xueyan Zhang, Runbo Zhong, Baohui Han

    Almmustuhtton 2022-03-01
    Fáttát:
    Viečča ollesdeavstta
    Artihkal
  6. 6
    Prophylactic treatment of dacomitinib‐induced skin toxicities in epidermal growth factor receptor‐mutated non–small‐cell lung cancer: A multicenter, Phase II trial

    Prophylactic treatment of dacomitinib‐induced skin toxicities in epidermal growth factor receptor‐mutated non–small‐cell lung cancer: A multicenter, Phase II trial Dahkki Masahiro Iwasaku, Junji Uchino, Kenji Chibana, Shigeru Tanzawa, Takahiro Yamada, Kazunori Tobino, Yasuki Uchida, Takashi Kijima, Katsumi Nakatomi, Miiru Izumi, Nobuyo Tamiya, Hideharu Kimura, Masaki Fujita, Ryoichi Honda, Chieko Takumi, Tadaaki Yamada, Yoshiko Kaneko, Fumiaki Kiyomi, Koichi Takayama

    Almmustuhtton 2023-07-01
    Fáttát: “…dacomitinib…”
    Viečča ollesdeavstta
    Artihkal
  7. 7
    A Novel Quantum Dots-Based Fluorescent Sensor for Determination of the Anticancer Dacomitinib: Application to Dosage Forms

    A Novel Quantum Dots-Based Fluorescent Sensor for Determination of the Anticancer Dacomitinib: Application to Dosage Forms Dahkki Manal A. Alossaimi, Heba Elmansi, Mai Alajaji, Ali Altharawi, Abdulmalik S. A. Altamimi, Galal Magdy

    Almmustuhtton 2023-03-01
    Fáttát:
    Viečča ollesdeavstta
    Artihkal
  8. 8
    Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report

    Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report Dahkki Qian Shen, Jingjing Qu, Zhen Chen, Jianying Zhou

    Almmustuhtton 2021-12-01
    Fáttát:
    Viečča ollesdeavstta
    Artihkal
  9. 9
    Remarkable response to dacomitinib in a patient with leptomeningeal carcinomatosis due to EGFR‐mutant non‐small cell lung cancer

    Remarkable response to dacomitinib in a patient with leptomeningeal carcinomatosis due to EGFR‐mutant non‐small cell lung cancer Dahkki Shun Mizusaki, Kohei Otsubo, Toshifumi Ninomiya, Hidenobu Arimura, Yuko Tsuchiya‐Kawano, Koji Inoue

    Almmustuhtton 2021-01-01
    Fáttát: “…Dacomitinib…”
    Viečča ollesdeavstta
    Artihkal
  10. 10
    Bevacizumab plus dacomitinib combination therapy for L858R‐mutated metastatic lung adenocarcinoma: A report of two cases

    Bevacizumab plus dacomitinib combination therapy for L858R‐mutated metastatic lung adenocarcinoma: A report of two cases Dahkki Chi‐Kang Teng, Chieh‐Lung Chen, Ting‐Han Chen, Wen‐Chien Cheng, Chih‐Yen Tu

    Almmustuhtton 2022-05-01
    Fáttát:
    Viečča ollesdeavstta
    Artihkal
  11. 11
    A real‐world study of dacomitinib in later‐line settings for advanced non‐small cell lung cancer patients harboring EGFR mutations

    A real‐world study of dacomitinib in later‐line settings for advanced non‐small cell lung cancer patients harboring EGFR mutations Dahkki Hong‐Shuai Li, Jin‐Yao Zhang, Xiang Yan, Hai‐Yan Xu, Xue‐Zhi Hao, Pu‐Yuan Xing, Yan Wang

    Almmustuhtton 2022-02-01
    Fáttát:
    Viečča ollesdeavstta
    Artihkal
  12. 12
    Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study

    Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study Dahkki Xingxiang Pu, Yu Zhou, Yi Kong, Bolin Chen, Aifang Yang, Jia Li, Kang Li, Yan Xu, Lin Wu

    Almmustuhtton 2023-10-01
    Fáttát:
    Viečča ollesdeavstta
    Artihkal
  13. 13
    Pan-EGFR Inhibitor Dacomitinib Resensitizes Paclitaxel and Induces Apoptosis via Elevating Intracellular ROS Levels in Ovarian Cancer SKOV3-TR Cells

    Pan-EGFR Inhibitor Dacomitinib Resensitizes Paclitaxel and Induces Apoptosis via Elevating Intracellular ROS Levels in Ovarian Cancer SKOV3-TR Cells Dahkki Ye Jin Lim, Hee Su Kim, Seunghee Bae, Kyeong A So, Tae Jin Kim, Jae Ho Lee

    Almmustuhtton 2024-01-01
    Fáttát: “…dacomitinib…”
    Viečča ollesdeavstta
    Artihkal
  14. 14
    Dacomitinib exhibits promising activity against the rare HER2 exon 20 insertion M774delinsWLV in lung cancer: A case report and literature review

    Dacomitinib exhibits promising activity against the rare HER2 exon 20 insertion M774delinsWLV in lung cancer: A case report and literature review Dahkki Guangjian Yang, Runze Liu, Xiaoyong Tang

    Almmustuhtton 2024-05-01
    Fáttát:
    Viečča ollesdeavstta
    Artihkal
  15. 15
    Olaparib Combined With Dacomitinib in Osimertinib-Resistant Brain and Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Report and Systematic Review

    Olaparib Combined With Dacomitinib in Osimertinib-Resistant Brain and Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Report and Systematic Review Dahkki Hui Zhang, Hui Zhang, Yong Wang, Huaguo Wu, Shizhen Zhou, Shuo Li, Xiangji Meng, Rongjie Tao, Jinming Yu, Jinming Yu

    Almmustuhtton 2022-04-01
    Fáttát:
    Viečča ollesdeavstta
    Artihkal
  16. 16
    Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China

    Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China Dahkki Hong-Shuai Li, Guang-Jian Yang, Yi Cai, Jun-Ling Li, Hai-Yan Xu, Tao Zhang, Li-Qiang Zhou, Yu-Ying Wang, Jin-Liang Wang, Xing-Sheng Hu, Xiang Yan, Yan Wang

    Almmustuhtton 2022-06-01
    Fáttát: “…dacomitinib…”
    Viečča ollesdeavstta
    Artihkal
  17. 17
    Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib

    Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib Dahkki Jian Liu, Swan Lin, Anthony Huynh, Weiwei Tan

    Almmustuhtton 2024-01-01
    Fáttát: “…dacomitinib…”
    Viečča ollesdeavstta
    Artihkal
  18. 18
    Case Report: Grade 4 pneumonitis occurred after thoracic radiotherapy and dacomitinib in a patient with lung adenocarcinoma

    Case Report: Grade 4 pneumonitis occurred after thoracic radiotherapy and dacomitinib in a patient with lung adenocarcinoma Dahkki Ailing Liu, Junxu Wen, Kaikai Zhao, Liyang Jiang, Xiangjiao Meng

    Almmustuhtton 2025-02-01
    Fáttát:
    Viečča ollesdeavstta
    Artihkal
  19. 19
    The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study

    The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world o... Dahkki Wen-Chien Cheng, Chi-Chien Lin, Wei-Chih Liao, Yu-Chao Lin, Chia-Hung Chen, Hung-Jen Chen, Chih-Yen Tu, Te-Chun Hsia

    Almmustuhtton 2024-02-01
    Fáttát:
    Viečča ollesdeavstta
    Artihkal
  20. 20
    EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios

    EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active... Dahkki Ikei S. Kobayashi, Hollis Viray, Deepa Rangachari, Susumu S. Kobayashi, Daniel B. Costa

    Almmustuhtton 2021-12-01
    Fáttát:
    Viečča ollesdeavstta
    Artihkal

Ohcanreaiddut: